w3 Search Results


92
Miltenyi Biotec anti rat cd4 apc vio770 miltenyi 130 107 504 rrid ab 2657949
Anti Rat Cd4 Apc Vio770 Miltenyi 130 107 504 Rrid Ab 2657949, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc11438102__12974_2024_3221_MOESM1_ESM-0-30-32?v=Miltenyi+Biotec
Average 92 stars, based on 1 article reviews
anti rat cd4 apc vio770 miltenyi 130 107 504 rrid ab 2657949 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

85
Cedarlane mouse igg1 clone w3 25 isotype controls
Mouse Igg1 Clone W3 25 Isotype Controls, supplied by Cedarlane, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc04640216-54-31-39?v=Cedarlane
Average 85 stars, based on 1 article reviews
mouse igg1 clone w3 25 isotype controls - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier

94
OriGene cd4 nm 012705 rat tagged orf clone
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Cd4 Nm 012705 Rat Tagged Orf Clone, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc13213619-196-0-9?v=OriGene
Average 94 stars, based on 1 article reviews
cd4 nm 012705 rat tagged orf clone - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

91
Cedarlane anti cd4
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Anti Cd4, supplied by Cedarlane, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc06180127-258-37-41?v=Cedarlane
Average 91 stars, based on 1 article reviews
anti cd4 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

93
Cedarlane cd4
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Cd4, supplied by Cedarlane, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc03521579-129-31-10?v=Cedarlane
Average 93 stars, based on 1 article reviews
cd4 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Miltenyi Biotec rea482 miltenyi biotec 130 107 668 p p38 mapk
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Rea482 Miltenyi Biotec 130 107 668 P P38 Mapk, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc10673909__42003_2023_5463_MOESM2_ESM-78-92-93?v=Miltenyi+Biotec
Average 93 stars, based on 1 article reviews
rea482 miltenyi biotec 130 107 668 p p38 mapk - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Thermo Fisher poly acrylic acid
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Poly Acrylic Acid, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pm25731156-53-20-31?v=Thermo+Fisher
Average 94 stars, based on 1 article reviews
poly acrylic acid - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

80
Cedarlane antirat t helper cell antibody cl003a
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Antirat T Helper Cell Antibody Cl003a, supplied by Cedarlane, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pm10908159-111-7-13?v=Cedarlane
Average 80 stars, based on 1 article reviews
antirat t helper cell antibody cl003a - by Bioz Stars, 2026-08
80/100 stars
  Buy from Supplier

90
Cedarlane anti cd43
(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human <t>CD4</t> + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .
Anti Cd43, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pm11081878-87-4-6?v=Cedarlane
Average 90 stars, based on 1 article reviews
anti cd43 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

86
Durect Corporation device at w3
Figure 6. Effect of the different implantable devices and the <t>refined</t> <t>stereotaxic</t> protocol on the percentage change in animal body weight at different timepoints. Note the striking drop in APP mice implanted with the original device at <t>W3</t> leading to us considering and applying a humane endpoint in this experimental group. Specific sample size is provided in Table 1. Data expressed as median and IQR. Kruskall–Wallis test for multiple comparisons (W0 and W3) and Mann–Whitney U test for independent pairwise comparisons (W8). * p < 0.05; ** p < 0.01. W, week.
Device At W3, supplied by Durect Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pm37627418-253-27-46?v=Durect+Corporation
Average 86 stars, based on 1 article reviews
device at w3 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

93
Proteintech rabbit anti hla dpa1 polyclonal antibody
Overview of using scRNA technology to study cancer liver metastasis
Rabbit Anti Hla Dpa1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/w3/pmc10839686-321-60-65?v=Proteintech
Average 93 stars, based on 1 article reviews
rabbit anti hla dpa1 polyclonal antibody - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


(A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human CD4 + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .

Journal: Cancer cell

Article Title: Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

doi: 10.1016/j.ccell.2026.03.015

Figure Lengend Snippet: (A) UMAP plots of human T cells ( n = 64) showing stage- and subtype-specific grouping (insets). (B) Quantification of T cell subsets (normal: n = 11; DCIS: n = 29; IBC: n = 24). Patients with <100 T cells were excluded. Unadjusted significance values were computed by Kruskal-Wallis test and Tukey’s multiple comparison. (C–E) Milo neighborhoods of human T cells (C) and DAs (Differential Abundances) in IBC vs. DCIS as shown by UMAP plot (D) or beeswarm plot (E). (F) UMAP plots of SD rat T cells ( n = 13) showing condition-specific grouping (inset). (G–I) Milo neighborhoods of rat T cells (G), enrichment in NMU-treated tumors vs. MGs (H), or beeswarm plot (I). Node size denotes cell numbers, and edges denote cells shared between connected neighborhoods. Beeswarm plots show LFC distribution at FDR 10% of neighborhoods between IBC vs. DCIS (E) or rat NMU-treated tumors vs. MGs (I). (J) UMAP plots of human CD4 + T cells. (K) Beeswarm plots of T cell neighborhoods and LFC distribution for pairwise comparisons between three IBC subtypes (IBC/HR + : n = 6; IBC/TNBC: n = 10; IBC/HER2 + : n = 8). UMAP, uniform manifold approximation projection; DAs,; LCF, log fold-change. See also and .

Article Snippet: Cd4 ( NM_012705 ) Rat Tagged ORF Clone , Origene , CAT#: RR210599.

Techniques: Comparison

(A) Schematic of ex vivo iTreg-DC co-culture. Bright-field images of dendriform morphologies typical of DCs. Scale bars, 10 μm. (B) Contour plots depicting CellTrace-CSFE dilution in dLN-derived iTreg following co-cultures with cDC1 or cDC2 derived from macroscopic tumors or microlesions, or with BM- or PBMC-derived moDCs. T 0 baseline (cyan) and iTreg monoculture (gray) are included. CSFE signal is visualized as contour overlays and as mode-normalized histogram. Asterisk indicates significant D4+ division shift in co-cultures with tumor-derived cDC2 (blue). (C) Line plots showing the proportions of dLN-derived iTreg entering division states D0-D4+ in monoculture or co-cultures with DC subsets, with/without blockade of immune synapse components (10 μg/mL per mAb) (across treatments: no DCs, n = 12; +tumor-cDC1 or cDC2, n = 6; +microlesion-cDC1 or cDC2, n = 9; +BM- or PBMC-derived DC, n = 12). Significance for each treatment was computed by two-way repeated-measures (RM) ANOVA and Dunnett’s multiple comparisons, with p values reported for D1 and D4+ states. Pooled-variance two-way ANOVA was applied for D4+ states to evaluate cross-treatment differences among DC subtypes. (D) The division index calculated as the peak-to-trough ratio of iTreg in D4+ relative to D2. Individual or interaction effects of DC co-culture and blockade conditions were assessed by two-way RM ANOVA. Tukey’s post-hoc analysis was used for TCR/MHC-II blockade in tumor-derived cDC2 co-cultures. (E) Trajectorial inference of human CD4 + grouped by progression stage (left) and Seurat clusters (right). Pseudotime values and molecular subtype are shown as insets. (F and G) TCR Shannon’s diversity index (F) and cytotoxic CD8 + scores (G) of primary breast tumors among PAM50 subtypes from the TCGA cohort (luminal A: n = 473; luminal B: n = 240; HER2 + : n = 90; basal: n = 189). Stratification was based on median cutoff of adjusted cycTreg score. Significance was computed using Wilcoxon rank-sum test. (H) cycTreg and non-cycTreg in pure DCIS (left) and IBC (right) classified as TN, HR + /HER2 − , and HR − /HER2 + (DCIS: TN, n = 13; HR + , n = 9; HR − /HER2 + , n = 6; IBC/DCIS: TN, n = 12; HR + , n = 11; HR − /HER2 + , n = 5). Dotted lines demarcate tumor-stroma borders. Rectangles denote magnified ROIs. Asterisks denote cycTreg. Scale bars, 250 μm and 10 μm (insets). (I and J) Multivariable linear regression of cycTreg stratified by DCIS or IBC, with tumor Ki67 + (I) and tumor size (J) as predicted outcomes. Covariate interactions were evaluated by least-square regression. (K and L) Logistic regression by nuclear grade outcomes (1: high vs. 0: low) based on cycTreg, with patients stratified by DCIS or IBC (K) or histologic subtypes (L). See also ; and .

Journal: Cancer cell

Article Title: Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

doi: 10.1016/j.ccell.2026.03.015

Figure Lengend Snippet: (A) Schematic of ex vivo iTreg-DC co-culture. Bright-field images of dendriform morphologies typical of DCs. Scale bars, 10 μm. (B) Contour plots depicting CellTrace-CSFE dilution in dLN-derived iTreg following co-cultures with cDC1 or cDC2 derived from macroscopic tumors or microlesions, or with BM- or PBMC-derived moDCs. T 0 baseline (cyan) and iTreg monoculture (gray) are included. CSFE signal is visualized as contour overlays and as mode-normalized histogram. Asterisk indicates significant D4+ division shift in co-cultures with tumor-derived cDC2 (blue). (C) Line plots showing the proportions of dLN-derived iTreg entering division states D0-D4+ in monoculture or co-cultures with DC subsets, with/without blockade of immune synapse components (10 μg/mL per mAb) (across treatments: no DCs, n = 12; +tumor-cDC1 or cDC2, n = 6; +microlesion-cDC1 or cDC2, n = 9; +BM- or PBMC-derived DC, n = 12). Significance for each treatment was computed by two-way repeated-measures (RM) ANOVA and Dunnett’s multiple comparisons, with p values reported for D1 and D4+ states. Pooled-variance two-way ANOVA was applied for D4+ states to evaluate cross-treatment differences among DC subtypes. (D) The division index calculated as the peak-to-trough ratio of iTreg in D4+ relative to D2. Individual or interaction effects of DC co-culture and blockade conditions were assessed by two-way RM ANOVA. Tukey’s post-hoc analysis was used for TCR/MHC-II blockade in tumor-derived cDC2 co-cultures. (E) Trajectorial inference of human CD4 + grouped by progression stage (left) and Seurat clusters (right). Pseudotime values and molecular subtype are shown as insets. (F and G) TCR Shannon’s diversity index (F) and cytotoxic CD8 + scores (G) of primary breast tumors among PAM50 subtypes from the TCGA cohort (luminal A: n = 473; luminal B: n = 240; HER2 + : n = 90; basal: n = 189). Stratification was based on median cutoff of adjusted cycTreg score. Significance was computed using Wilcoxon rank-sum test. (H) cycTreg and non-cycTreg in pure DCIS (left) and IBC (right) classified as TN, HR + /HER2 − , and HR − /HER2 + (DCIS: TN, n = 13; HR + , n = 9; HR − /HER2 + , n = 6; IBC/DCIS: TN, n = 12; HR + , n = 11; HR − /HER2 + , n = 5). Dotted lines demarcate tumor-stroma borders. Rectangles denote magnified ROIs. Asterisks denote cycTreg. Scale bars, 250 μm and 10 μm (insets). (I and J) Multivariable linear regression of cycTreg stratified by DCIS or IBC, with tumor Ki67 + (I) and tumor size (J) as predicted outcomes. Covariate interactions were evaluated by least-square regression. (K and L) Logistic regression by nuclear grade outcomes (1: high vs. 0: low) based on cycTreg, with patients stratified by DCIS or IBC (K) or histologic subtypes (L). See also ; and .

Article Snippet: Cd4 ( NM_012705 ) Rat Tagged ORF Clone , Origene , CAT#: RR210599.

Techniques: Ex Vivo, Co-Culture Assay, Derivative Assay

(A) Pseudotime trajectory of rat T cells. (B) OX40 ligand-receptor expression across cell types within rat macroscopic tumors and microlesions. (C) % TIL subtypes with OX40, CTLA4, 4–1BB, and LAG3 positivity ( n = 15 tumors). (D) Schematic of rat immunotherapy study coupled with EdU/BrdU dual pulse chase. (E) Spaghetti plots of individual tumor growth curves (isotype: n = 16; αOX40: n = 15; αPD-L1: n = 16; combo: n = 23). (F) Derivative distribution of the growth rate of individual tumors quantified as negative (blue) or positive (red) peak area-under-curve (AUC). (G) Tumor volumes at 10-day post initial treatment. (H and I) Flow diagram of cycTreg density (H) and frequency of cycTreg and non-cycTreg (I). (J) Ratios of total Treg, cycTreg, and non-cycTreg to total infiltrated CD8 + T cells. (K) EdU/BrdU contours of TILs. Quadrants denote EdU + /BrdU + distribution. (L and M) Frequency of BrdU + , EdU + , or double-labeled cycTreg (L) and non-cycTreg (M). Significance was computed by two-way ANOVA and Dunnet’s multiple comparison relative to BrdU-labeling. (N) Linear regression of cycTreg with CD8 + Tconv (red) and CD4 + Tconv (green). Dots in each color represent individual tumors ( n = 64). Pearson’s best-fit parameters including R 2 , slope, and significance, and 95% CI are shown. In (C) and (F), significance was computed by two-way ANOVA and Dunn’s multiple comparison. In (E), values are shown in log 10 scale to show very small tumors in responding groups. Pre- or on-treatment tumors are specified. In (J), values are shown in log 2 scale to show tumors with low Treg infiltration. See also and .

Journal: Cancer cell

Article Title: Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

doi: 10.1016/j.ccell.2026.03.015

Figure Lengend Snippet: (A) Pseudotime trajectory of rat T cells. (B) OX40 ligand-receptor expression across cell types within rat macroscopic tumors and microlesions. (C) % TIL subtypes with OX40, CTLA4, 4–1BB, and LAG3 positivity ( n = 15 tumors). (D) Schematic of rat immunotherapy study coupled with EdU/BrdU dual pulse chase. (E) Spaghetti plots of individual tumor growth curves (isotype: n = 16; αOX40: n = 15; αPD-L1: n = 16; combo: n = 23). (F) Derivative distribution of the growth rate of individual tumors quantified as negative (blue) or positive (red) peak area-under-curve (AUC). (G) Tumor volumes at 10-day post initial treatment. (H and I) Flow diagram of cycTreg density (H) and frequency of cycTreg and non-cycTreg (I). (J) Ratios of total Treg, cycTreg, and non-cycTreg to total infiltrated CD8 + T cells. (K) EdU/BrdU contours of TILs. Quadrants denote EdU + /BrdU + distribution. (L and M) Frequency of BrdU + , EdU + , or double-labeled cycTreg (L) and non-cycTreg (M). Significance was computed by two-way ANOVA and Dunnet’s multiple comparison relative to BrdU-labeling. (N) Linear regression of cycTreg with CD8 + Tconv (red) and CD4 + Tconv (green). Dots in each color represent individual tumors ( n = 64). Pearson’s best-fit parameters including R 2 , slope, and significance, and 95% CI are shown. In (C) and (F), significance was computed by two-way ANOVA and Dunn’s multiple comparison. In (E), values are shown in log 10 scale to show very small tumors in responding groups. Pre- or on-treatment tumors are specified. In (J), values are shown in log 2 scale to show tumors with low Treg infiltration. See also and .

Article Snippet: Cd4 ( NM_012705 ) Rat Tagged ORF Clone , Origene , CAT#: RR210599.

Techniques: Expressing, Pulse Chase, Labeling, Comparison

(A and B) CellChat heatmap of outgoing signaling in treatment-naïve tumors (A) (FDR <0.05) and chord diagram (B) inferring Il33 (green) from CAFs to Il1rl1 (blue, encoding ST2) on cycTreg and eTreg. (C) Pearson’s correlations of proximity scores from MIBI dataset of DCIS epithelium edge to CD45 + immune cells and to CAFs. Best-fit R 2 was computed based on recurrence diagnosis. Each dot represents individual DCIS patients ( n = 55) with follow-up for IBC recurrence (red, n = 14) or lack thereof (blue, n = 41). (D) Linear regression of adjusted cycTreg score with IL33 (top) and IL1RL1 (bottom) expression from TCGA dataset ( n = 992 patients). (E and F) Tumor volumes (E) and % CGR (F) computed at tumor endpoints (isotype: n = 26; αIL-33: n = 26). Tumors with < 7 days of in vivo growth were excluded. Significance was computed using two-tailed Mann-Whitney U test. (G) UMAP plot of 29 TIL clusters inferred by Phenograph. Heatmap insets show scaled fluorescence values. (H–M) Quantification of total CD4 + FOXP3 + Treg (H), cycTreg (I), ratios of total Treg (J), cycTreg (K), and non-cycTreg (L) to total CD8 + , and Eomes hi CD45RC hi memory-effector CD8 + T cells (M). (N–Q) Contours of IRF8/IRF4 (N) and RT1B/RT1A (P) and quantified myeloid IRF8 (O) and RT1A (MHC-I) (Q) of intratumor cDC1, cDC2, TAMs, and TILs. (R and S) Pearson’s correlations of cDC2 with cycTreg (R) and non-cycTreg (S) following αIL-33 blocking. Pearson’s best-fit parameters including R 2 , significance, and 95% CI are shown. For αIL-33 study, individual tumors are shown (isotype: n = 38; αIL-33: n = 26 tumors). Significance of two-group comparisons (E, F, and H–M) was computed by two-tailed Student’s t test. Significance of multiple group comparisons (O and Q) was computed by two-way ANOVA and Sidak’s multiple comparison. See also and .

Journal: Cancer cell

Article Title: Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

doi: 10.1016/j.ccell.2026.03.015

Figure Lengend Snippet: (A and B) CellChat heatmap of outgoing signaling in treatment-naïve tumors (A) (FDR <0.05) and chord diagram (B) inferring Il33 (green) from CAFs to Il1rl1 (blue, encoding ST2) on cycTreg and eTreg. (C) Pearson’s correlations of proximity scores from MIBI dataset of DCIS epithelium edge to CD45 + immune cells and to CAFs. Best-fit R 2 was computed based on recurrence diagnosis. Each dot represents individual DCIS patients ( n = 55) with follow-up for IBC recurrence (red, n = 14) or lack thereof (blue, n = 41). (D) Linear regression of adjusted cycTreg score with IL33 (top) and IL1RL1 (bottom) expression from TCGA dataset ( n = 992 patients). (E and F) Tumor volumes (E) and % CGR (F) computed at tumor endpoints (isotype: n = 26; αIL-33: n = 26). Tumors with < 7 days of in vivo growth were excluded. Significance was computed using two-tailed Mann-Whitney U test. (G) UMAP plot of 29 TIL clusters inferred by Phenograph. Heatmap insets show scaled fluorescence values. (H–M) Quantification of total CD4 + FOXP3 + Treg (H), cycTreg (I), ratios of total Treg (J), cycTreg (K), and non-cycTreg (L) to total CD8 + , and Eomes hi CD45RC hi memory-effector CD8 + T cells (M). (N–Q) Contours of IRF8/IRF4 (N) and RT1B/RT1A (P) and quantified myeloid IRF8 (O) and RT1A (MHC-I) (Q) of intratumor cDC1, cDC2, TAMs, and TILs. (R and S) Pearson’s correlations of cDC2 with cycTreg (R) and non-cycTreg (S) following αIL-33 blocking. Pearson’s best-fit parameters including R 2 , significance, and 95% CI are shown. For αIL-33 study, individual tumors are shown (isotype: n = 38; αIL-33: n = 26 tumors). Significance of two-group comparisons (E, F, and H–M) was computed by two-tailed Student’s t test. Significance of multiple group comparisons (O and Q) was computed by two-way ANOVA and Sidak’s multiple comparison. See also and .

Article Snippet: Cd4 ( NM_012705 ) Rat Tagged ORF Clone , Origene , CAT#: RR210599.

Techniques: Biomarker Discovery, Expressing, In Vivo, Two Tailed Test, MANN-WHITNEY, Fluorescence, Blocking Assay, Comparison

Figure 6. Effect of the different implantable devices and the refined stereotaxic protocol on the percentage change in animal body weight at different timepoints. Note the striking drop in APP mice implanted with the original device at W3 leading to us considering and applying a humane endpoint in this experimental group. Specific sample size is provided in Table 1. Data expressed as median and IQR. Kruskall–Wallis test for multiple comparisons (W0 and W3) and Mann–Whitney U test for independent pairwise comparisons (W8). * p < 0.05; ** p < 0.01. W, week.

Journal: Animals : an open access journal from MDPI

Article Title: Refining Stereotaxic Neurosurgery Techniques and Welfare Assessment for Long-Term Intracerebroventricular Device Implantation in Rodents.

doi: 10.3390/ani13162627

Figure Lengend Snippet: Figure 6. Effect of the different implantable devices and the refined stereotaxic protocol on the percentage change in animal body weight at different timepoints. Note the striking drop in APP mice implanted with the original device at W3 leading to us considering and applying a humane endpoint in this experimental group. Specific sample size is provided in Table 1. Data expressed as median and IQR. Kruskall–Wallis test for multiple comparisons (W0 and W3) and Mann–Whitney U test for independent pairwise comparisons (W8). * p < 0.05; ** p < 0.01. W, week.

Article Snippet: In this regard, and in agreement with the aforementioned results, the percentage change in body weight decreased in all animals undergoing stereotaxic surgery, regardless of the implanted device at W3 (p WT naïve vs. original= 0.001; p WT naïve vs. miniaturized= 0.004; p WT original vs. Alzet = 0.045; p WT miniaturized vs. Alzet = 0.044; p APP naïve vs. original < 0.001; p APP naïve vs. miniaturized = 0.002; p APP original vs. Alzet = 0.006; Figure 6).

Techniques: MANN-WHITNEY

Figure 7. Effect of changes in the dimensions of implanted device and the refined stereotaxic protocol on animal welfare throughout the experiment. (a) Representation (top) and heatmap (bottom) of the median welfare assessment scores throughout the duration of the experiment for each experimental group. The higher the scores, the more compromised the welfare of animals. It is important to point out the elevated scores obtained in both WT and APP mice implanted with the original device and following the traditional protocol at W2 and W3, which resulted in the application of humane endpoint and termination of the experiment for this experimental group at this timepoint. No statistical test has been performed for these data over time due to the incompatibility with the wide variety of experiment termination. (b) Quantification of animal welfare at timepoints shared by most experimental groups, i.e., W3 and W8. (c) Pre- and post-representations of animal welfare scores at W1 vs. W3 vs. W8 or W1 vs. W3, for each experimental group individually. Specific sample size is provided in Table 1. Data expressed as median and IQR. Kruskal–Wallis test for multiple comparisons (W3 in (b)); Mann–Whitney U test for independent pairwise comparisons (WT vs. APP comparisons in b; W8 in (b)); Friedman test for multiple comparisons with repeated measures (naïve and miniaturized in (c)); and Wilcoxon test for dependent pairwise comparisons (original and Alzet in (c)). * p < 0.05; ** p < 0.01, for differences between experimental groups based on the implanted device and multiple comparisons; # p < 0.05; for differences between WT and APP genotypes in (b) (see Figure S2 for detailed analysis).

Journal: Animals : an open access journal from MDPI

Article Title: Refining Stereotaxic Neurosurgery Techniques and Welfare Assessment for Long-Term Intracerebroventricular Device Implantation in Rodents.

doi: 10.3390/ani13162627

Figure Lengend Snippet: Figure 7. Effect of changes in the dimensions of implanted device and the refined stereotaxic protocol on animal welfare throughout the experiment. (a) Representation (top) and heatmap (bottom) of the median welfare assessment scores throughout the duration of the experiment for each experimental group. The higher the scores, the more compromised the welfare of animals. It is important to point out the elevated scores obtained in both WT and APP mice implanted with the original device and following the traditional protocol at W2 and W3, which resulted in the application of humane endpoint and termination of the experiment for this experimental group at this timepoint. No statistical test has been performed for these data over time due to the incompatibility with the wide variety of experiment termination. (b) Quantification of animal welfare at timepoints shared by most experimental groups, i.e., W3 and W8. (c) Pre- and post-representations of animal welfare scores at W1 vs. W3 vs. W8 or W1 vs. W3, for each experimental group individually. Specific sample size is provided in Table 1. Data expressed as median and IQR. Kruskal–Wallis test for multiple comparisons (W3 in (b)); Mann–Whitney U test for independent pairwise comparisons (WT vs. APP comparisons in b; W8 in (b)); Friedman test for multiple comparisons with repeated measures (naïve and miniaturized in (c)); and Wilcoxon test for dependent pairwise comparisons (original and Alzet in (c)). * p < 0.05; ** p < 0.01, for differences between experimental groups based on the implanted device and multiple comparisons; # p < 0.05; for differences between WT and APP genotypes in (b) (see Figure S2 for detailed analysis).

Article Snippet: In this regard, and in agreement with the aforementioned results, the percentage change in body weight decreased in all animals undergoing stereotaxic surgery, regardless of the implanted device at W3 (p WT naïve vs. original= 0.001; p WT naïve vs. miniaturized= 0.004; p WT original vs. Alzet = 0.045; p WT miniaturized vs. Alzet = 0.044; p APP naïve vs. original < 0.001; p APP naïve vs. miniaturized = 0.002; p APP original vs. Alzet = 0.006; Figure 6).

Techniques: MANN-WHITNEY

Figure 8. Effect of implantation of smaller devices following refined intrathecal implantation proce- dures on general and anxiety-like behaviors. (a,b) Dorsal views of two different mice implanted with the miniaturized device at W3 and W8 (a), and with the Alzet pump at W3 and W4 (b), following in both cases the optimized surgery protocol. Note the good general appearance of the animals and of

Journal: Animals : an open access journal from MDPI

Article Title: Refining Stereotaxic Neurosurgery Techniques and Welfare Assessment for Long-Term Intracerebroventricular Device Implantation in Rodents.

doi: 10.3390/ani13162627

Figure Lengend Snippet: Figure 8. Effect of implantation of smaller devices following refined intrathecal implantation proce- dures on general and anxiety-like behaviors. (a,b) Dorsal views of two different mice implanted with the miniaturized device at W3 and W8 (a), and with the Alzet pump at W3 and W4 (b), following in both cases the optimized surgery protocol. Note the good general appearance of the animals and of

Article Snippet: In this regard, and in agreement with the aforementioned results, the percentage change in body weight decreased in all animals undergoing stereotaxic surgery, regardless of the implanted device at W3 (p WT naïve vs. original= 0.001; p WT naïve vs. miniaturized= 0.004; p WT original vs. Alzet = 0.045; p WT miniaturized vs. Alzet = 0.044; p APP naïve vs. original < 0.001; p APP naïve vs. miniaturized = 0.002; p APP original vs. Alzet = 0.006; Figure 6).

Techniques:

Overview of using scRNA technology to study cancer liver metastasis

Journal: iScience

Article Title: Single-cell transcriptomics reveals the role of antigen presentation in liver metastatic breast cancer

doi: 10.1016/j.isci.2024.108896

Figure Lengend Snippet: Overview of using scRNA technology to study cancer liver metastasis

Article Snippet: The sections were stained for three panels by using 4-color Novo-Light multiplex fluorescence immunohistochemistry: panel 1 including Rabbit anti-FCN3 (C-term) Polyclonal Antibody (abs101543, Absin), Rabbit anti-C1QC Polyclonal Antibody (A9227, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin); panel 2 including Rabbit anti-XCR1 (D2F8T) Monoclonal Antibody (44665S, CST), Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin), Rabbit anti-HLA-DQA1 Polyclonal Antibody (16918-1-AP, Proteintech) and Rabbit anti-HLA-DPA1 Polyclonal Antibody (16109-1-AP, Proteintech); panel 3 including Rabbit anti-LAMP3 Polyclonal Antibody (A2895, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin).

Techniques: Sequencing, RNA Sequencing, Migration

Clinical verification of alteration and function of FCN3 + macrophage, cDC1 and LAMP3 + DC in LM (A) Ratio of FCN3 + C1QC + HLA-E + cells, XCR1 + HLA-E + cells, XCR1 + HLA-DQA1 + cells, XCR1 + HLA-DPA1 + cells and LAMP3 + HLA-E + cells in normal mammary ducts or lobules, primary tumor of invasive ductal breast carcinoma (above phase 3C, staged by AJCC 6 th Edition) and liver metastasis. (B) Representative immunofluorescence appearance of FCN3 + C1QC + HLA-E + cells, XCR1 + HLA-E + cells, XCR1 + HLA-DQA1 + cells, XCR1 + HLA-DPA1 + cells and LAMP3 + HLA-E + cells (above phase 3c, staged by AJCC 6 th Edition). Panel 1 (left): blue for DAPI, green for FCN3, purple for C1QC and red for HLA-E; panel 2 (middle): blue for DAPI, green for XCR1, red for HLA-E, purple for HLA-DQA1 and yellow for HLA-DPA1; panel 3 (right): blue for DAPI, green for LAMP3 and red for HLA-E. Scale bar: 20 μm. (C) Analysis of OS between patients with high and low levels of MHC signature score filtered by top and bottom 25% values of XCR1 and LAMP3 from the TCGA-BRCA cohort. (D) Analysis of OS between patients with high and low levels of MHC signature score filtered by top and bottom 25% values of LAMP3 from the TCGA-LIHC cohort. In bar plots, Student’s t test was performed. p < 0.05∗, p < 0.01∗∗, p < 0.001∗∗∗, p < 0.0001∗∗∗∗. In survival analysis, Log rank was used to calculate the p value, p < 0.05 was considered to be significant.

Journal: iScience

Article Title: Single-cell transcriptomics reveals the role of antigen presentation in liver metastatic breast cancer

doi: 10.1016/j.isci.2024.108896

Figure Lengend Snippet: Clinical verification of alteration and function of FCN3 + macrophage, cDC1 and LAMP3 + DC in LM (A) Ratio of FCN3 + C1QC + HLA-E + cells, XCR1 + HLA-E + cells, XCR1 + HLA-DQA1 + cells, XCR1 + HLA-DPA1 + cells and LAMP3 + HLA-E + cells in normal mammary ducts or lobules, primary tumor of invasive ductal breast carcinoma (above phase 3C, staged by AJCC 6 th Edition) and liver metastasis. (B) Representative immunofluorescence appearance of FCN3 + C1QC + HLA-E + cells, XCR1 + HLA-E + cells, XCR1 + HLA-DQA1 + cells, XCR1 + HLA-DPA1 + cells and LAMP3 + HLA-E + cells (above phase 3c, staged by AJCC 6 th Edition). Panel 1 (left): blue for DAPI, green for FCN3, purple for C1QC and red for HLA-E; panel 2 (middle): blue for DAPI, green for XCR1, red for HLA-E, purple for HLA-DQA1 and yellow for HLA-DPA1; panel 3 (right): blue for DAPI, green for LAMP3 and red for HLA-E. Scale bar: 20 μm. (C) Analysis of OS between patients with high and low levels of MHC signature score filtered by top and bottom 25% values of XCR1 and LAMP3 from the TCGA-BRCA cohort. (D) Analysis of OS between patients with high and low levels of MHC signature score filtered by top and bottom 25% values of LAMP3 from the TCGA-LIHC cohort. In bar plots, Student’s t test was performed. p < 0.05∗, p < 0.01∗∗, p < 0.001∗∗∗, p < 0.0001∗∗∗∗. In survival analysis, Log rank was used to calculate the p value, p < 0.05 was considered to be significant.

Article Snippet: The sections were stained for three panels by using 4-color Novo-Light multiplex fluorescence immunohistochemistry: panel 1 including Rabbit anti-FCN3 (C-term) Polyclonal Antibody (abs101543, Absin), Rabbit anti-C1QC Polyclonal Antibody (A9227, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin); panel 2 including Rabbit anti-XCR1 (D2F8T) Monoclonal Antibody (44665S, CST), Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin), Rabbit anti-HLA-DQA1 Polyclonal Antibody (16918-1-AP, Proteintech) and Rabbit anti-HLA-DPA1 Polyclonal Antibody (16109-1-AP, Proteintech); panel 3 including Rabbit anti-LAMP3 Polyclonal Antibody (A2895, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin).

Techniques: Immunofluorescence

Journal: iScience

Article Title: Single-cell transcriptomics reveals the role of antigen presentation in liver metastatic breast cancer

doi: 10.1016/j.isci.2024.108896

Figure Lengend Snippet:

Article Snippet: The sections were stained for three panels by using 4-color Novo-Light multiplex fluorescence immunohistochemistry: panel 1 including Rabbit anti-FCN3 (C-term) Polyclonal Antibody (abs101543, Absin), Rabbit anti-C1QC Polyclonal Antibody (A9227, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin); panel 2 including Rabbit anti-XCR1 (D2F8T) Monoclonal Antibody (44665S, CST), Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin), Rabbit anti-HLA-DQA1 Polyclonal Antibody (16918-1-AP, Proteintech) and Rabbit anti-HLA-DPA1 Polyclonal Antibody (16109-1-AP, Proteintech); panel 3 including Rabbit anti-LAMP3 Polyclonal Antibody (A2895, Abclonal) and Mouse anti-HLA-E Monoclonal Antibody (abs154728, Absin).

Techniques: Recombinant, Lysis, Staining, Software